Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
158 hedge funds and large institutions have $1.36B invested in Momenta Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 74 increasing their positions, 33 reducing their positions, and 18 closing their positions.
467% more call options, than puts
Call options by funds: $3.65M | Put options by funds: $644K
124% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 33
12% more capital invested
Capital invested by funds: $1.21B → $1.36B (+$148M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 164 → 158 (-6)
22% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.1M |
| 2 |
BlackRock
New York
|
+$16.6M |
| 3 |
Renaissance Technologies
New York
|
+$10.9M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.74M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$20.8M |
| 2 |
AC
Armistice Capital
New York
|
-$11.5M |
| 3 |
SGA
Sector Gamma AS
Oslo,
Norway
|
-$4.77M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.1M |
| 5 |
Goldman Sachs
New York
|
-$3.83M |
MNTA Hedge Fund Activity: Q3 2017 in Review
158 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2017, worth a combined $1.36B — up 12% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of MNTA and 14 opened new positions — a net loss of 4 holders — while 33 trimmed existing stakes and 74 added.
The largest buyer was Wellington Management Group, adding an estimated $23.1M. The largest seller was Discovery Capital Management, exiting entirely with an estimated $20.8M sold.
- 158 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2017, down from 164 in Q2 2017.
- Funds reported $1.36B of Momenta Pharmaceuticals, Inc. stock for Q3 2017, up 12% quarter-over-quarter.
- 14 funds opened new Momenta Pharmaceuticals, Inc. positions in Q3 2017 and 18 closed out, a net change of -4 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2017 was Wellington Management Group, an estimated $23.1M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q3 2017 was Discovery Capital Management, an estimated $20.8M sold.
Based on aggregated 13F filings for Q3 2017.